Lanean...
Suppression of autophagy by BCR/ABL
Imatinib and second generation BCR/ABL tyrosine kinase inhibitors (TKIs) serve now as standard therapies for patients with chronic myelogenous leukemia (CML); however, CML stem cells are intrinsically insensitive to the cell death-inducing effects of TKIs, allowing the persistence of a “reservoir” o...
Gorde:
| Argitaratua izan da: | Leuk Lymphoma |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2011
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7416844/ https://ncbi.nlm.nih.gov/pubmed/21250825 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2010.546913 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|